Avacta Reports Encouraging AVA6000 Salivary Gland Cancer Data at ASCO 2026
LONDON and PHILADELPHIA, June 1, 2026 Avacta Therapeutics announced updated Phase 1a/1b clinical results for faridoxorubicin (AVA6000) at the...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LONDON and PHILADELPHIA, June 1, 2026 Avacta Therapeutics announced updated Phase 1a/1b clinical results for faridoxorubicin (AVA6000) at the...
LONDON and PHILADELPHIA, December 17, 2025 — Avacta Therapeutics, a clinical-stage biopharmaceutical company, has reported positive Phase 1b clinical...
